JP2022517433A5 - - Google Patents

Info

Publication number
JP2022517433A5
JP2022517433A5 JP2021541666A JP2021541666A JP2022517433A5 JP 2022517433 A5 JP2022517433 A5 JP 2022517433A5 JP 2021541666 A JP2021541666 A JP 2021541666A JP 2021541666 A JP2021541666 A JP 2021541666A JP 2022517433 A5 JP2022517433 A5 JP 2022517433A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weight
cgrp antagonist
breakthrough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014239 external-priority patent/WO2020150703A1/en
Publication of JP2022517433A publication Critical patent/JP2022517433A/ja
Publication of JP2022517433A5 publication Critical patent/JP2022517433A5/ja
Pending legal-status Critical Current

Links

JP2021541666A 2019-01-20 2020-01-19 突出性の片頭痛を処置するためのcgrpアンタゴニスト Pending JP2022517433A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962794665P 2019-01-20 2019-01-20
US62/794,665 2019-01-20
US201962844169P 2019-05-07 2019-05-07
US62/844,169 2019-05-07
US201962893206P 2019-08-29 2019-08-29
US62/893,206 2019-08-29
US201962910284P 2019-10-03 2019-10-03
US62/910,284 2019-10-03
US202062959088P 2020-01-09 2020-01-09
US62/959,088 2020-01-09
PCT/US2020/014239 WO2020150703A1 (en) 2019-01-20 2020-01-19 Cgrp antagonists for treating migraine breakthrough

Publications (2)

Publication Number Publication Date
JP2022517433A JP2022517433A (ja) 2022-03-08
JP2022517433A5 true JP2022517433A5 (cg-RX-API-DMAC7.html) 2022-09-22

Family

ID=71613964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541666A Pending JP2022517433A (ja) 2019-01-20 2020-01-19 突出性の片頭痛を処置するためのcgrpアンタゴニスト

Country Status (13)

Country Link
US (2) US20210338654A1 (cg-RX-API-DMAC7.html)
EP (1) EP3911409A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022517433A (cg-RX-API-DMAC7.html)
KR (1) KR20210116560A (cg-RX-API-DMAC7.html)
CN (1) CN113316470A (cg-RX-API-DMAC7.html)
AU (1) AU2020210024A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011546A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127328A1 (cg-RX-API-DMAC7.html)
IL (1) IL284947A (cg-RX-API-DMAC7.html)
MX (1) MX2021008191A (cg-RX-API-DMAC7.html)
PH (1) PH12021551689A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106721VA (cg-RX-API-DMAC7.html)
WO (1) WO2020150703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
DK4088720T3 (da) * 2018-03-25 2025-09-29 Pfizer Ireland Pharmaceuticals Unlimited Company Rimegepant til cgrp-relaterede lidelser
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TW202019459A (zh) * 2018-07-05 2020-06-01 愛爾蘭商歐樂根製藥國際有限公司 Cgrp拮抗劑及梭菌衍生物之組合療法
WO2021005494A1 (en) * 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders
JP2022549167A (ja) 2019-09-18 2022-11-24 マサチューセッツ インスティテュート オブ テクノロジー 鋭いエッジを生産するためのシステム、組成物、および方法
EP4034156A4 (en) * 2019-09-25 2024-01-24 Allergan Pharmaceuticals International Limited COMBINATION THERAPY WITH CGRP ANTAGONISTS
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
CA3202137A1 (en) * 2020-11-19 2022-05-27 Pfizer Ireland Pharmaceuticals Compositions for improved delivery of cgrp inhibitors
IT202000029459A1 (it) * 2020-12-03 2022-06-03 Alberto Chiarugi Terapia dei disturbi emotivi
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024505509A (ja) * 2021-02-01 2024-02-06 ファイザー アイルランド ファーマシューティカルズ Cgrp阻害薬の医薬組成物およびそれらを使用する方法
CN117999078A (zh) * 2021-03-02 2024-05-07 Cgrp诊断公司 偏头痛的发生的治疗和/或降低
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
US20240366618A1 (en) * 2021-10-11 2024-11-07 Pfizer Ireland Pharmaceuticals CGRP Antagonists for Treating Trigeminal Neuralgia
CN114053232A (zh) * 2021-11-23 2022-02-18 莱默(北京)药业科技有限公司 一种乌布吉泮冻干口崩片及制备方法
WO2023177823A1 (en) * 2022-03-17 2023-09-21 Vasoceuticals, Inc. Combined use of individual compounds for treatment of chronic pain disorders
US20240358695A1 (en) * 2023-04-25 2024-10-31 Aurobindo Pharma Ltd Pharmaceutical Compositions of Rimegepant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
RS56556B1 (sr) * 2012-02-27 2018-02-28 Bristol Myers Squibb Co N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so
SMT202600087T1 (it) * 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
DK4088720T3 (da) * 2018-03-25 2025-09-29 Pfizer Ireland Pharmaceuticals Unlimited Company Rimegepant til cgrp-relaterede lidelser
US20190374518A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TW202019459A (zh) * 2018-07-05 2020-06-01 愛爾蘭商歐樂根製藥國際有限公司 Cgrp拮抗劑及梭菌衍生物之組合療法

Similar Documents

Publication Publication Date Title
US20170216212A1 (en) Tapentadol compositions
US20070184109A1 (en) Compositions comprising triptans and nsaids
CN102395276A (zh) 硝唑尼特的控制释放药物剂型
EP1919473B1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique
JP2012021025A (ja) メロキシカムを含む組成物
US20080026054A1 (en) Novel anelgesic combination
JP2022516662A5 (cg-RX-API-DMAC7.html)
BG102669A (bg) Метод за лечение и фармацевтичен състав
CN1141937C (zh) 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
US20210196685A1 (en) Composition for eradicating helicobacter pylori
CN1726035A (zh) 非甾体抗炎药、解充血药和抗组胺药的组合物
WO2005094832A1 (en) Compositions comprising meloxicam
US20050038018A1 (en) Meloxicam compositions
CN120129522A (zh) 用于治疗化脓性汗腺炎的方法和组合物
EP3432931A1 (en) Pharmaceutical compositons for n-propargylamine derivative
CN101360756A (zh) 治疗胃肠道病症的方法和组合物
JP2024084670A5 (cg-RX-API-DMAC7.html)
JP2021518438A (ja) 男性の避妊のための非ホルモン性組成物および方法
JP2009535336A (ja) 片頭痛治療用の固定組合せ剤形
CN112263581A (zh) 一种治疗pe和ed的双层片复方制剂及其制备方法
HK1047547B (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
CN115887462A (zh) 一种口服药物组合物
RU2025133530A (ru) Лечение бокового амиотрофического склероза (бас)
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
ZA200509860B (en) Composition comprising triptans and NSAIDS